[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[$vani](/topic/$vani)

### Sentiment: XX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$vani/c:line/m:sentiment.svg)  
[Sentiment 24-Hour Chart Data](/topic/$vani/time-series/sentiment.tsv)  
**Current Value**: XX%  
**Daily Average**: XX%  
**1 Month**: XX% +14%  
**1-Year High**: XXX% on 2025-06-11  
**1-Year Low**: XX% on 2025-06-24  

**Most Supportive Themes**
- **Cardiometabolic Benefits:** (30%) Positive outcomes associated with GLP-1 receptor agonist therapy, including improved cardiometabolic outcomes, weight loss, and reduced risk of heart disease.
- **Hormonal and Sleep Benefits:** (15%) The potential of GLP-1 drugs to boost testosterone levels in men and improve sleep quality, leading to better weight loss results.
- **Market Expansion:** (10%) The expansion of Hims & Hers into Canada and the availability of Wegovy in Singapore, indicating market growth and accessibility.
- **New Research and Developments:** (5%) The emergence of new research and developments in GLP-1 therapies, including oral medications and gene editing approaches.
  
**Most Critical Themes**
- **GLP-1 Drug Risks:** (25%)  Concerns about the risks and side effects of GLP-1 drugs, including potential for optic nerve damage, gastroesophageal reflux disease, and mental health issues.
- **Cost and Economic Concerns:** (10%)  Criticism of the high cost and economic inefficiency of GLP-1 drugs, particularly in the context of Medicare coverage.
- **Unsupervised Use and Misleading Practices:** (5%)  Warnings against unsupervised use of weight-loss drugs and the potential for misleading advertising and pricing practices.
  
Network engagement breakdown:  
| Network | Positive | %   | Neutral | %   | Negative | %   |
| ------- | -------- | -   | ------- | -   | -------- | -   |
| X       | XXXXX    | XX% | XXXXXX  | XX% | XXXXX    | XX% |
|         |          |     |         |     |          |     |
| Total   | XXXXX    | XX% | XXXXXX  | XX% | XXXXX    | XX% |